Kim Nygård, Riitta Ryhänen, Aaron Kortteenniemi, Kajsa Järvinen, Aino Vesikansa, Juha Mehtälä, Mirkka Koivusalo, Annakaisa Tirronen, Eralda Asllanaj, Jarmo Kaukua, Sami Pakarinen, Juha Tuominen
{"title":"Identification of Patient Clusters with Distinct Disease Progression Patterns Utilizing a Nationwide Finnish Population with Type 2 Diabetes.","authors":"Kim Nygård, Riitta Ryhänen, Aaron Kortteenniemi, Kajsa Järvinen, Aino Vesikansa, Juha Mehtälä, Mirkka Koivusalo, Annakaisa Tirronen, Eralda Asllanaj, Jarmo Kaukua, Sami Pakarinen, Juha Tuominen","doi":"10.1007/s13300-026-01879-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Variability in the clinical presentation of patients with type 2 diabetes (T2D) is high and underlines the need for more personalized patient care. This nationwide study aimed to describe characteristics, treatment patterns, and disease progression of Finnish patients with T2D (N = 302,987), and to identify patient clusters with distinct progression patterns based on the occurrence of diabetes-related complications.</p><p><strong>Methods: </strong>The study included all adult patients with incident T2D in Finland between 2010 and 2019. Data were collected from national health and social care registers, data lakes, and a private healthcare provider between 1996 and 2021. Patient clusters were identified based on disease progression, defined by the occurrence of 22 pre-defined end-points, using likelihood-based growth mixture modeling.</p><p><strong>Results: </strong>Five patient clusters with stable (C1; n = 133,951), mild (C2; n = 52,819), moderate (C3, n = 43,488), rapid (C4; n = 10,159), and extremely rapid progression (C5; n = 1973) were identified. The mean number of end-point complications per patient at baseline ranged from 0.2 to 2.3 across clusters and remained stable in C1-C3 over the first 5 years. In C5, the number increased to 5.5 and 7.2 during the first and third follow-up years, respectively, with a similar but more modest annual increase observed in C4. Cardiovascular complications increased more rapidly in C5 and C4 than C1-C3. T2D medication use was more common in milder clusters, whereas 31.4% and 48.2% of patients in C4 and C5, respectively, had no T2D medication. The rate of certain infections and values of creatinine, hemoglobin, and erythrocytes, increased with cluster severity.</p><p><strong>Conclusions: </strong>Diagnosis of several other new conditions, particularly cardiovascular complications, at or soon after incident T2D diagnosis predicts poor prognosis. The results further support a comprehensive approach in diabetes care, including evaluation and treatment of cardiovascular diseases alongside glycemic control.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1043-1065"},"PeriodicalIF":4.2000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13388581/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-026-01879-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Variability in the clinical presentation of patients with type 2 diabetes (T2D) is high and underlines the need for more personalized patient care. This nationwide study aimed to describe characteristics, treatment patterns, and disease progression of Finnish patients with T2D (N = 302,987), and to identify patient clusters with distinct progression patterns based on the occurrence of diabetes-related complications.
Methods: The study included all adult patients with incident T2D in Finland between 2010 and 2019. Data were collected from national health and social care registers, data lakes, and a private healthcare provider between 1996 and 2021. Patient clusters were identified based on disease progression, defined by the occurrence of 22 pre-defined end-points, using likelihood-based growth mixture modeling.
Results: Five patient clusters with stable (C1; n = 133,951), mild (C2; n = 52,819), moderate (C3, n = 43,488), rapid (C4; n = 10,159), and extremely rapid progression (C5; n = 1973) were identified. The mean number of end-point complications per patient at baseline ranged from 0.2 to 2.3 across clusters and remained stable in C1-C3 over the first 5 years. In C5, the number increased to 5.5 and 7.2 during the first and third follow-up years, respectively, with a similar but more modest annual increase observed in C4. Cardiovascular complications increased more rapidly in C5 and C4 than C1-C3. T2D medication use was more common in milder clusters, whereas 31.4% and 48.2% of patients in C4 and C5, respectively, had no T2D medication. The rate of certain infections and values of creatinine, hemoglobin, and erythrocytes, increased with cluster severity.
Conclusions: Diagnosis of several other new conditions, particularly cardiovascular complications, at or soon after incident T2D diagnosis predicts poor prognosis. The results further support a comprehensive approach in diabetes care, including evaluation and treatment of cardiovascular diseases alongside glycemic control.
导言:2型糖尿病(T2D)患者临床表现的可变性很高,强调了对更多个性化患者护理的需求。这项全国性的研究旨在描述芬兰T2D患者的特征、治疗模式和疾病进展(N = 302,987),并根据糖尿病相关并发症的发生确定具有不同进展模式的患者群。方法:该研究纳入了2010年至2019年芬兰所有发生T2D的成年患者。数据收集自1996年至2021年期间的国家卫生和社会保健登记册、数据湖和私人医疗保健提供者。使用基于似然的生长混合模型,根据疾病进展(由22个预定义终点的发生来定义)确定患者群。结果:共鉴定出5组患者,分别为稳定(C1, n = 133,951)、轻度(C2, n = 52,819)、中度(C3, n = 43,488)、快速(C4, n = 10,159)和极快速(C5, n = 1973)。在基线时,每个患者的平均终点并发症数量在0.2到2.3之间,并且在前5年中C1-C3保持稳定。在C5,这一数字在第一年和第三年分别增加到5.5和7.2,在C4中观察到类似但更温和的年增长。心血管并发症在C5和C4比C1-C3增加更快。T2D药物的使用在较轻的群集中更为常见,而C4和C5分别有31.4%和48.2%的患者没有T2D药物。某些感染的比率和肌酐、血红蛋白和红细胞的值随着群集的严重程度而增加。结论:在t2dm发病时或发病后不久诊断其他几种新情况,特别是心血管并发症,预示预后不良。结果进一步支持糖尿病护理的综合方法,包括心血管疾病的评估和治疗以及血糖控制。
期刊介绍:
Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.